ICH Q5D: Derivation and Characterisation of Cell Substrates
ICH Q5D provides the harmonised framework for the derivation, banking, characterisation, and testing of cell substrates used to manufacture biotechnological and biological products. The current Step 4 guideline, dated 16 July 1997, applies to human and animal cell lines as well as microbial cells that are managed through a cell-banking system. Its central principle is that the quality and safety of a biological product are closely linked to the history, identity, purity, stability, and control of the cells used to manufacture it. Q5D therefore addresses the origin and development history of a cell substrate, exposure to human- or animal-derived materials, generation of production cell lines, Master Cell Bank (MCB) and Working Cell Bank (WCB) systems, cryopreservation, traceability, identity testing, microbial and viral purity, cross-contamination control, stability through the proposed in vitro cell age, and selected karyology or tumorigenicity considerations. The guideline also includes an appendix for primary cell substrates, which are not banked in the same way but still require a structured safety and source-control strategy.
What Is ICH Q5D?
ICH Q5D is formally titled Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products. The guideline provides broad recommendations for deriving human and animal cell lines and microbial cells, preparing production cell banks, characterising those banks, and presenting the relevant information in marketing applications.
It complements other biotechnology quality guidelines by focusing specifically on the biological starting system: the cell substrate that ultimately generates the product.
For related biotechnology quality topics, see the ICH Quality Guidelines.
Why Cell Substrate Control Matters
Q5D explains that historical quality concerns for cell-derived biological products have arisen from two broad sources: adventitious contaminants and properties of the cells themselves. Recombinant DNA-derived products also raise questions about the expression construct carried by the production cell.
Because the cell substrate can influence product identity, quality, safety, and consistency, effective control of the product requires appropriate control of the way the cell substrate is derived, handled, banked, stored, tested, and used.
Scope of ICH Q5D
Q5D applies to cell substrates that are maintained through a cell-banking system. In the guideline, a cell substrate may be a microbial cell or a cell line derived from human or animal sources with the capacity to generate the intended biotechnology or biological product for human in vivo or ex vivo use.
| Included in Q5D | Outside or specially treated by Q5D |
|---|---|
| Continuous human or animal cell lines | Reagents for in vitro diagnostic use |
| Diploid cells with finite in vitro lifespan | Microbial metabolites such as antibiotics, amino acids, carbohydrates and other low-molecular-weight substances |
| Bacteria, fungi, yeast and other unicellular microbial sources | Primary cells are not banked and are therefore outside the main cell-banking sections, but Appendix 1 provides relevant principles |
| Cell banks used for gene therapy products or vaccines | — |
Source, History, and Generation of the Cell Substrate
Q5D places substantial importance on reconstructing the history of the production cell substrate and, where relevant, the parental cell line from which it was derived. Research and development events can materially affect the risk assessment.
Origin and source documentation
The source laboratory or culture collection should be identified, and relevant scientific references should be cited. Information directly from the source laboratory is preferred when available.
Human cell lines
Relevant information can include the original tissue or organ, geographical background, age, sex, physiological condition, health or medical history where known, and testing for pathogenic agents. For human diploid fibroblasts, donor age may be relevant because it can influence in vitro lifespan.
Animal cell lines
The source description can include species, strain, breeding conditions, tissue or organ, geographical origin, age, sex, health status, and testing for pathogenic agents.
Microbial cell substrates
Manufacturers should describe species, strain, known genotypic and phenotypic characteristics, pathogenicity, toxin production, and other relevant biohazards.
Cultivation and manipulation history
The history should document isolation, culture conditions, procedures used to establish the cell line, genetic manipulation or selection, and available information on endogenous and adventitious agents.
Q5D also expects a careful review of possible exposure to infectious agents during cell-substrate generation. Culture-media constituents of human or animal origin—such as serum, enzymes, hydrolysates, or other living cells—should be described with their source, preparation method, control strategy, test results, and quality assurance information.
Generation of the production cell substrate
A suitable parental cell line is a critical starting point. For recombinant products, the parental cell line is typically the untransfected recipient cell line. Q5D suggests, but does not make essential, the use of a characterised parental cell bank.
Procedures used during development may include cell fusion, transfection, selection, colony isolation, cloning, gene amplification, and adaptation to specific media or culture conditions. These steps should be documented because they help explain the biological history and potential risks of the final cell substrate.
For recombinant products, the production cell substrate is generally the transfected cell containing the desired sequence and cloned from a single-cell progenitor. For hybridoma products, it is the hybridoma cell line generated from fusion of the relevant parental cells.
Cell Banking Systems: MCB and WCB
One of the core advantages of a banked-cell manufacturing system is the ability to start different production lots from a characterised common source.
Two-tiered banking system
Q5D describes a two-tier system—an MCB used to generate one or more WCBs—as the generally accepted and most practical approach for continued manufacture.
| Bank | Role in Q5D | Typical use |
|---|---|---|
| Master Cell Bank (MCB) | Generally prepared from the selected initial clone or a preliminary bank. | Source used to derive WCBs and anchor long-term production consistency. |
| Working Cell Bank (WCB) | Derived from one or more MCB containers and qualified by testing and characterisation. | Typically used to provide cells directly for manufacturing. |
Manufacturers should describe how they will maintain a continuing supply of cells, including expected use rates, the anticipated interval between new banks, and qualification criteria.
Single-tier systems
A single-tier system using only an MCB can be acceptable in principle—for example, when only a small number of containers is required each year.
Microbial transformation systems
Q5D also recognises a different approach for some microbial expression systems. A new transformation can be performed for each new transformed-cell-bank lot using thoroughly tested host-cell and plasmid banks. In such cases, the transformed bank is treated as the MCB, provided the transformation and banking system is appropriately documented and controlled.
Cell Banking Procedures and Storage Controls
Q5D stresses that preventive controls are essential because no testing programme can detect every possible contaminant.
Information to document
- Type of banking system.
- Bank size.
- Containers and closure systems.
- Media and cryoprotectants.
- Preparation, freezing, cryopreservation, and storage conditions.
- Procedures to prevent microbial contamination and cell-line cross-contamination.
- Traceability and a durable labelling system.
Use of a single pooled cell suspension
When multiple culture vessels are used to generate a bank, Q5D recommends combining the cells into a single pool before dispensing so that individual bank containers have uniform composition.
Cryopreservation
Animal cells may be frozen under defined conditions using a cryoprotectant and then stored in liquid-nitrogen vapour or liquid phase, or at an equivalent ultra-low temperature. Alternative preservation methods can be acceptable if they maintain consistent and adequate viability for production use.
Business continuity and disaster protection
Q5D explicitly asks manufacturers to consider protection against catastrophic loss of a cell bank. Examples include multiple storage freezers, back-up power, automated liquid-nitrogen filling, storage of part of the MCB/WCB at remote locations, or regeneration strategies.
General Principles of Cell Bank Characterisation
Q5D describes bank characterisation as a critical control for biotechnology and biological products. The objective is to confirm the identity, purity, and suitability of the cell substrate for manufacturing use.
| Stage | General Q5D expectation |
|---|---|
| MCB | Identity and purity testing once for each MCB; stability during cultivation generally assessed once for each product registration. |
| WCB | Purity testing and limited identity testing once for each WCB. |
| Production-age cells | Evaluation of suitability and stability at or beyond the proposed in vitro cell-age limit. |
The exact testing programme depends on biological properties, growth requirements, cultivation history, use of human- or animal-derived materials, and available methods. More extensive characterisation at the cell-bank level may reduce the need for some later routine testing.
Q5D also encourages the use of state-of-the-art methods as technology improves, provided newer methods offer specificity, sensitivity, and precision at least equivalent to the methods they replace.
Cell Bank Identity Testing
Metazoan cells
Q5D allows either phenotypic or genotypic characteristics to support cell identity. For adherent human or animal cells, morphology can be useful when combined with other tests.
The guideline gives examples such as isoenzyme analysis, banding cytogenetics, species-specific antisera, marker chromosomes, and DNA-based polymorphism analysis. Either confirmation of species origin or demonstration of unique known cell-line markers is considered adequate. Expression of the desired product can provide complementary identity evidence.
Microbial cells
For many microbial banks, growth on selective media is generally adequate to confirm host-cell identity at the species level. Additional approaches may be useful for particular strains, such as phage typing for some E. coli systems. Expression of the intended product may also support identity of the microbial expression system.
Cell Bank Purity Testing
Q5D defines biological purity as freedom from adventitious microbial agents and adventitious cellular contaminants.
Bioburden and sterility-related testing
For metazoan MCBs and WCBs, Q5D states that bioburden testing for bacteria and fungi should be performed on individual containers representing 1% of the total bank, but not fewer than two containers. The guideline recognises suitable pharmacopoeial microbial-limit or sterility procedures.
For related pharmacopoeial resources, see the European Pharmacopoeia, JP, and USP.
Mycoplasma testing
Mycoplasma testing should be performed on the MCB and WCB. Q5D cites agar/broth culture and indicator-cell culture procedures as suitable approaches in the context of the guideline.
Virus testing
Viral testing should be designed to detect a broad range of possible viruses using appropriate screening and specific tests selected according to the history of the cell line. Q5D directs applicants to the relevant ICH viral-safety guideline.
Cross-contamination by other cell lines
Q5D recognises that purity can also be compromised by another cell line of the same or a different species. Where other cell lines were present during open banking manipulations, the bank should be tested for evidence of those other cells or their products.
Microbial cell banks
Purity testing for microbial banks should be designed around likely contaminants based on the source organism, culture materials, scientific literature, and other organisms handled in the banking laboratory. Colony morphology across suitable media can be useful as a contaminant-detection tool.
Cell Substrate Stability and In Vitro Cell Age
Q5D identifies two major stability concerns:
- Consistent production of the intended product during cultivation.
- Retention of adequate production capacity during storage of the bank.
Stability during production culture
At least two time points should be examined: one using cells that have undergone a minimal number of subcultivations and another using cells at or beyond the proposed limit of in vitro cell age.
The proposed limit should be supported using cells expanded under pilot-plant or commercial-scale conditions to the proposed limit or beyond. The starting reference point for in vitro cell-age calculations is the thawing of one or more MCB containers.
Recombinant expression systems
For recombinant cell lines, Q5D expects consistency of the expression construct coding sequence to be verified in cells cultivated to the production-age limit or beyond, using nucleic-acid testing or product analysis as described in the relevant ICH expression-construct guideline.
Other stability markers
Where the desired product cannot be assessed directly, other characteristics may be used, such as morphology, growth properties, biochemical or immunological markers, productivity, oxygen consumption, glucose consumption, ammonia generation, or lactate production.
Increasing the cell-age limit
If the authorised or proposed in vitro cell-age limit is increased, Q5D expects supporting data from cells expanded to the proposed new limit.
Stability of the cryopreserved bank
Bank stability can be monitored through viability and performance when containers are thawed for manufacture or when a new WCB is prepared. If production does not occur for an extended period, viability testing should be performed at the interval specified in the marketing application.
Karyology and Tumorigenicity Testing
Q5D treats karyology and tumorigenicity as product- and cell-substrate-dependent tools rather than universal requirements.
Extensive analysis of aneuploid-cell frequency is not considered useful. Karyology does not need to be determined for rodent cell lines or other new cell lines already known to be non-diploid, although cytogenetic methods can still support identity or purity testing.
For highly purified products that contain no cells, karyology and tumorigenicity testing are generally not considered necessary when appropriate residual host-cell DNA limits are consistently met through process validation or lot-release testing.
Products in which live cells cannot be excluded, or which undergo little downstream purification, may require more extensive cell-substrate characterisation. New or previously uncharacterised diploid cell substrates should have diploid karyology confirmed and tumorigenic potential established.
MRC-5 and WI-38
Q5D states that genetically unmodified MRC-5 and WI-38 cells do not need repeated karyology or tumorigenicity characterisation because extensive information already exists. However, each newly generated WCB should be confirmed once to remain diploid and to have the expected lifespan when grown under the intended production conditions.
Appendix 1: Primary Cell Substrates
Primary cell cultures are handled differently because they are used at the first passage after isolation from tissue and therefore cannot undergo the same extensive characterisation before use as banked cell substrates.
Q5D groups the information for primary cells into three broad categories:
- Source tissue and other animal-derived raw materials.
- Preparation of the primary cell substrate.
- Testing performed to support product safety.
Source animals
Tissue should be obtained from healthy animals monitored for pathogenic agents. Where possible, animals should come from closed or specific-pathogen-free colonies or flocks, should not previously have been used for experimental studies, and should be appropriately quarantined.
Raw materials and reagents
The identity and source of human- or animal-derived materials should be documented, including testing performed to demonstrate the absence of detectable contaminants and adventitious agents.
Preparation and testing
Isolation, establishment, and maintenance of primary cultures should be described. Because extensive prior characterisation is not practical, testing for adventitious agents may occur concurrently with production and can include observation of cultures, indicator-cell inoculation, examination for cytopathic effects, testing for hemadsorbing viruses, and specific-agent testing where required.
Practical Quality-System Implementation
Q5D was issued in 1997, but its control principles remain highly compatible with modern pharmaceutical quality systems. Cell-bank operations should be governed by approved SOP documents and appropriate cGMP controls.
Electronic inventory records, thaw/use logs, cell-history records, test results, storage-location records, labels, investigation records, and stability-monitoring data should remain complete and traceable in accordance with ALCOA+ principles.
Where cryostorage or monitoring systems are formally qualified, lifecycle documentation may include URS, DQ, IQ, OQ, and PQ, where appropriate.
Unexpected contamination, bank mix-ups, labelling failures, unexplained viability loss, or recurrent storage excursions should be evaluated through formal investigation and, where needed, CAPA.
Common ICH Q5D Implementation Mistakes
- Focusing only on final bank testing. Q5D expects documentation of the entire cell-substrate history, including parental cells, manipulation, culture history, and exposure to biological raw materials.
- Assuming testing can eliminate all contamination risk. Q5D explicitly recognises that no testing regimen detects every contaminant, which is why preventive controls during banking are essential.
- Using poorly defined WCB qualification criteria. New WCBs should be appropriately characterised and tested before routine manufacturing use.
- Ignoring cross-contamination risk from other cell lines. Open manipulations require additional care and may trigger targeted testing.
- Failing to justify the in vitro cell-age limit. The limit should be supported by representative production cells grown to the limit or beyond.
- Neglecting bank disaster-recovery planning. Q5D specifically highlights protection against power loss, equipment failure, fire, and human error.
- Applying karyology or tumorigenicity testing universally. Q5D expects a risk- and product-based decision rather than a one-size-fits-all test package.
- Treating primary cells like conventional MCB/WCB systems. Primary cell substrates require a different source-control and concurrent-testing strategy.
ICH Q5D Cell Substrate Checklist
- Define the cell-substrate scope. Identify whether the system is human, animal, microbial, recombinant, hybridoma, or primary-cell based.
- Document origin and history. Record the source, donor/organism characteristics, isolation method, culture history, manipulations, and prior test results.
- Map biological raw-material exposure. Document serum, enzymes, hydrolysates, cells, or other human-/animal-derived inputs and their controls.
- Describe generation of the production substrate. Include transfection, fusion, cloning, selection, amplification, and adaptation steps where relevant.
- Define the banking strategy. Describe MCB/WCB structure, bank size, expected utilisation, re-banking plan, and qualification criteria.
- Control banking procedures. Establish pooling, aliquoting, cryopreservation, labelling, traceability, contamination prevention, and storage conditions.
- Perform identity and purity testing. Select phenotypic/genotypic identity tests and microbiological, mycoplasma, viral, or cross-contamination tests appropriate to the cell history.
- Establish in vitro cell-age stability. Compare low-age cells with cells at or beyond the proposed production limit.
- Assess special characterisation needs. Determine whether karyology, tumorigenicity, residual host-cell DNA, or primary-cell-specific controls are applicable.
- Maintain lifecycle oversight. Monitor bank stability, disaster recovery, new WCB qualification, storage performance, and investigation/CAPA throughout the bank's life.
Key Takeaways
- ICH Q5D covers derivation and characterisation of cell substrates used to manufacture biotechnology and biological products.
- The current Step 4 version is dated 16 July 1997.
- The guideline covers human and animal cell lines and microbial cells managed through cell-banking systems.
- Cell-substrate history, cultivation, genetic manipulation, and exposure to human- or animal-derived materials are central to risk assessment.
- A two-tier MCB/WCB system is generally the most practical approach, although justified single-tier and alternative microbial systems are possible.
- No testing programme can detect every potential contaminant; preventive controls during banking are therefore essential.
- MCBs are generally tested for identity and purity, while WCBs receive purity and limited identity testing.
- For metazoan banks, Q5D specifies bioburden sampling of 1% of bank containers, with a minimum of two containers.
- Cell-substrate stability should be assessed at a low cell age and again at or beyond the proposed in vitro production-age limit.
- Karyology, tumorigenicity, and primary-cell controls are applied according to the cell substrate, product, purification strategy, and risk.
Conclusion
ICH Q5D establishes the cell substrate and cell bank as fundamental components of biotechnology product quality. Its approach begins well before routine production: manufacturers are expected to understand where the cells came from, how they were manipulated, what biological materials they encountered, how they were banked, and whether they remain identifiable, pure, stable, and suitable for manufacture.
A strong Q5D program therefore combines documented cell history, preventive contamination control, qualified MCB/WCB systems, risk-based identity and purity testing, justified in vitro cell-age limits, bank-stability monitoring, and appropriate special characterisation. Integrated into a modern cGMP quality system, these principles provide a durable scientific foundation for consistent and safe production of biological medicines.
Frequently Asked Questions About ICH Q5D
1. What is ICH Q5D?
ICH Q5D is the ICH guideline for deriving, banking, characterising, and testing cell substrates used to manufacture biotechnology and biological products.
2. What types of cells are covered by ICH Q5D?
The guideline covers human and animal cell lines, including continuous and diploid lines, and microbial cells such as bacteria, fungi, yeast, and other unicellular organisms when managed through a cell-banking system.
3. What is the difference between an MCB and a WCB?
The Master Cell Bank is the primary characterised source bank. Working Cell Banks are generated from the MCB and are typically used to provide cells directly for manufacturing.
4. Is a two-tier MCB/WCB system mandatory?
No. Q5D describes the two-tier system as generally accepted and practical, but a justified single-tier system can be used in some situations.
5. What testing is generally performed on an MCB?
Q5D expects identity and purity testing once for each MCB and an evaluation of cell-substrate stability during cultivation for each registered product.
6. What testing is generally performed on a WCB?
Purity testing and limited identity testing should generally be performed once on each WCB.
7. How many MCB/WCB containers are tested for bioburden?
For metazoan banks, Q5D states that individual containers representing 1% of the total bank, but not fewer than two containers, should be tested for bacterial and fungal bioburden.
8. How is cell-substrate stability evaluated?
At least two cultivation time points should be assessed: cells with minimal subcultivation and cells at or beyond the proposed in vitro cell-age limit for production.
9. Does every cell line require tumorigenicity testing?
No. Q5D applies karyology and tumorigenicity testing according to the cell type, product, purification process, and risk. Highly purified cell-free products may not require these tests when residual host-cell DNA is adequately controlled.
10. How does Q5D address primary cell substrates?
Primary cells are not part of the standard banked-cell system, so Appendix 1 focuses on source-animal controls, raw materials, preparation methods, and concurrent testing for adventitious agents.
Editorial source note: This article is an original explanatory adaptation of ICH Q5D, Derivation and Characterisation of Cell Substrates Used for Production of Biotechnological/Biological Products. Practical quality-system commentary is included to improve usability and is clearly distinguished from source-derived requirements. This article does not replace the official ICH guideline, approved dossier, regional regulatory requirements, or product-specific specifications.
.webp)
